Post‐Covid Alzheimer and Its Remediation via PROTACs Therapy: A Comprehensive Review
COVID-19 may intensify AD pathogenesis through mechanisms that include tau hyperphosphorylation, underscoring the need for targeted interventions. PROTACs offer a mechanistically distinct, protein-degradation-based approach with promise for modifying tau-mediated disease; rigorous preclinical and clinical studies are warranted to establish feasibility, safety, and therapeutic impact in AD.
Authors
- Arup Kumar Mitra (ORCID: https://orcid.org/0000-0001-8983-6960)
- Ritojo Basu
- Bikram Dhara
- Ajoy Kumer
- Sk Asfaque Ali
- Teesta Bhowmick
Institutions
- International University of Business Agriculture and Technology (BD)
- Saroj Gupta Cancer Centre & Research Institute (IN)
- Saveetha University (IN)
- St Xavier’s College (IN)
Publication Details
- Journal
- Health Science Reports
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1002/hsr2.71631
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00